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COST OF POOR ADHERENCE TO ANTI-HYPERTENSIVE THERAPY 
IN 5 EUROPEAN COUNTRIES 
 
ABSTRACT 
Background: The financial burden for EU health systems associated with cardiovascular 
disease has been estimated to be nearly € 110 billion in 2006, corresponding to 10% of total 
healthcare expenditure across EU or a mean € 223 annual cost per capita. The main 
purpose of this study is to estimate the costs related to hypertension and the economic 
impact of increasing adherence to anti-hypertensive therapy in 5 European countries 
(Italy, Germany, France, Spain and England). 
Methods: A probabilistic prevalence-based decision tree model was developed to estimate 
the direct costs of cardiovascular disease related to hypertension (CV defined as: stroke, 
heart attack, kidney disease, heart failure) in 5 European countries. Our model considered 
adherence to hypertension treatment as a main driver of blood pressure control (BP < 
140/90 mmHg). Relative risk of CV, based on controlled or uncontrolled BP group, was 
estimated from the Framingham Heart Study and national review data. Prevalence and 
cost data were estimated from national literature reviews. A National Health System 
(NHS) perspective for 10 years was considered. Probabilistic Sensitivity Analysis (PSA) 
was performed in order to evaluate uncertainty around the results (given as 95% 
confidence intervals). 
Results: The model estimated a total of 8.6 million (1.4 in Italy, 3.3 in Germany, 1.2 in 
Spain, 1.8 in France and 0.9 in England) CV events related to hypertension over the 10 year 
time horizon. Increasing the adherence rate to anti-hypertensive therapy to 70% (baseline 
value is different for each country) would lead to 82,235 fewer CV events (24,058 in Italy, 
7,870 in Germany, 18,870 in Spain, 24,855 in France and 6,553 in England). From the NHS 
perspective, the direct cost associated with hypertension was estimated to be € 51.1 billion 
(8.1 in Italy, 17.8 in Germany, 12.2 in Spain, 8.8 in France and 4.1 in England). Increasing 
adherence to anti-hypertensive therapy to 70% would save a total of € 323.7 million (CI 
95%: € 304.2 - € 342.2 million) from the NHSs perspective. 
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Conclusion: This study is the first attempt to estimate the economic impact of non-
adherence amongst patients with diagnosed hypertension in Europe, using data from five 
European countries (Italy, France, Germany, Spain and England).  
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Introduction 
Safe and effective treatments for a range of health issues are widely available in Europe. 
These treatments, however, are not always used to their full potential. They can be limited 
by many factors, including a lack of adherence to treatment. The reasons behind low 
adherence are complex, and can include a variety of factors (such as socio-economic status, 
patient beliefs and lifestyle, health-literacy) and their interaction with the health care 
system. 
Better adherence to medical treatment, as well as medical and prevention plans, will 
improve the quality of life of patients and help support the long term sustainability of 
health care systems.1 
In Europe, about 4.58 million people die every year due to cardiovascular diseases (CV)2. 
In the 25 European countries, the annual expenditure for the treatment of CVs is estimated 
to be about € 169 billion3. Of this, about 61% is attributable to direct healthcare costs. 
The treatment of hypertension, one of the main risk factors, reduces the number of adverse 
cardiovascular events and thus decreases the economic and health impact of hypertension 
related CV4, 5, 6. The effectiveness of therapies used to treat hypertension has been shown 
to be closely related to the patients’ medical adherence to treatment7, 8. A level of good 
adherence needed for a pharmacological treatment to be effective, is widely recognized to 
be around 80% of the prescribed therapy9. Existing research shows that in several 
European countries less than 60% of treated hypertensive subjects have an adherence to 
their treatment over 80%10,11,12,13,14. Poor adherence results in severe losses in terms of 
clinical efficacy and economic efficiency, especially as the cardiovascular events that full 
adherence could avoid translate into greater hospitalization costs. 
Non-adherence to anti-hypertensive drugs remains a global issue and one of the main 
clinical obstacles to the reduction of cardiovascular morbidity and mortality. One study15 
has estimated that in the United States 100% adherence to treatment could reduce the risk 
of CV by 32%, with 8.5 million fewer events over 10 years follow-up and cumulative 
savings to the health care system of $ 72 billion15. To date this is the only systematic 
analysis published, but its results cannot be transferred directly to Europe, since there 
exist considerable variations in healthcare systems both between the United States and 
Europe, and between different European countries. The main purpose of this study is 
therefore to estimate the total cost of CV related to hypertension and the economic impact 
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of non-adherence to medical anti-hypertensive therapy in five European countries 




A prevalence based probabilistic model was developed to estimate the costs and 
consequences of CV, using risk equations to estimate the risk of cardiovascular events 
based on the Framingham Heart Study. The model simulates the natural history of the 
disease, where patients residing in each of the countries included in the analysis may or 
may not be hypertensive (Figure 1). Hypertensive patients (BP ≥ 140/90) may or may not 
be diagnosed with hypertension. The model assumes that all diagnosed patients are 
treated and that adherence to treatment (defined as the extent to which a patient acts in 
accordance with the prescribed interval and dose of a dosing regimen16) is the main driver 
for the patient to achieve a controlled blood pressure (BP < 140/90) and consequently a 
lower probability of experiencing a cardiovascular event. 
The model assumes that all undiagnosed hypertensive patients have an uncontrolled BP 
while the non-hypertensive subjects maintain a BP <140/90. On the basis of the 
Framingham17 risk equations, all subjects, including those who are not hypertensive, have 
a defined probability of experiencing a CV event. 
The model is used to produce a risk estimate over a 10 year period. Costs are estimated 
from a health system perspective using demographic, epidemiological and economic data 
obtained from national and international literature for each country included in the 
analysis. 
 
Figure 1 - Decision Tree Model 
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Cardiovascular Disease (CV) event 
The cardiovascular risk equation reported by D’Agostino et al. (2008)17 produces estimates 
of the risk of CV which varies depending on the patient’s age and other demographic 
characteristics, on clinical parameters including BP and on other risk factors. In our model 
the population has been divided into 4 risk groups: diagnosed subjects with controlled BP 
(BP < 140/90) after treatment, diagnosed subjects with uncontrolled BP (BP ≥ 140/90) after 
treatment, hypertensive but undiagnosed subjects (BP ≥ 140/90) and healthy subjects (BP< 
140/90). Within each risk group, the composition by age of the population of each country 
included in the analysis (Appendix A) was considered. 
The sum of cardiovascular risk scores, by BP risk group and age-weighted, produced the 
10-year CV event probabilities shown in Table 1. 
In order to estimate the costs of CV events attributable to hypertension, we considered a 
percentage of CV events that was assumed (by literature review) related to hypertension 
(Appendix B table B-1)15. As the focus of this study relates to costs of hypertension and 
non-adherence to therapy, healthy subjects were not considered in our cost analysis. 
 
Table 1 –10 year CV event probability by risk group and country of residence (age-weighted) 
Risk group ITALY GERMANY SPAIN FRANCE ENGLAND 
Diagnosed Controlled →  
Hypertension Event (FEMALE) 4.50% 4.50% 4.50% 4.50% 4.50% 
Diagnosed Uncontrolled →  
Hypertension Event (FEMALE) 10.00% 10.00% 8.60% 10.00% 10.00% 
Diagnosed Controlled →  
Hypertension Event (MALE) 9.40% 9.40% 7.90% 9.40% 7.90% 
Diagnosed Uncontrolled →  
Hypertension Event (MALE) 13.20% 15.60% 13.20% 13.20% 13.20% 
Undiagnosed Uncontrolled →  
Hypertension Event (FEMALE) 10.00% 10.00% 8.60% 10.00% 10.00% 
Undiagnosed Uncontrolled →  
Hypertension Event (MALE) 13.20% 15.60% 13.20% 13.20% 13.20% 
Untreated Controlled →  
Hypertension Event (FEMALE) 3.30% 3.30% 3.30% 3.30% 3.30% 
Untreated  Controlled →  
Hypertension Event (MALE) 6.70% 6.70% 5.60% 6.70% 5.60% 
Processing of the Framingham Heart Study by the authors17. 
Demographic and epidemiological data 
Demographic and epidemiological parameter values for each country are included in the 
analysis, and information about the prevalence of diagnosed and undiagnosed to 
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hypertension and treatment adherence were obtained from national and international 
literature: values and sources are reported in Table 2.  
Table 2 – Demographic and epidemiological parameters 
Demographic data ITALY GERMANY SPAIN FRANCE ENGLAND 
General Population 60,626,442[18] 81,843,743[19] 46,815,916[20] 65,281,000[21] 52,642,500[22] 
Percentage of Female 51.48%[18] 50.87%[19] 50.65%[20] 51.57%[21] 50.84%[22] 
Percentage of Female - Age ≥ 30 years 71.76%[18] 70.86%[19] 69.37%[20] 64.76%[21] 63.54%[22] 
Percentage of Male - Age ≥ 30 years 68.59%[18] 68.33%[19] 67.05%[20] 61.39%[21] 61.17%[22] 
Percentage of FEMALE with 
hypertension - Age ≥ 30 years 31.00%
[23] 50.30%[24] 31.70%[25, 26] 36.42%[27] 32.10%[28] 
Percentage of MALE with 
hypertension - Age ≥ 30 years 33.00%
[23] 60.20%[24] 44.60%[25, 26] 47.62%[29] 35.12%[28] 
Percentage of diagnosed and treated 
hypertensive subjects 73.00%
[30] 77.00%[31] 59.40%[26] 56.92%[27, 29] 58.38%[32] 
Percentage of diagnosed patients 
with adherence ≥ 80% 41.50%
[9] 66.90%[13] 39.40%[14] 39.00%[12] 56.85%[11] 
 
Estimate of direct healthcare costs 
In accordance with the perspective of the analysis, only direct healthcare costs associated 
with the treatment and control of hypertension and all related  CV events were 
considered. Regarding drug costs, two different approaches were used depending on 
available data for each country. The annual average cost for prescribed drugs was 
estimated in Italy and France from a top-down perspective as follows: annual 
pharmaceutical expenditure per ATC groups C02, C03, C07, C08 (antihypertensives, 
diuretics, beta blocking agents, calcium channel blockers), C09 (agents acting on the renin-
angiotensin system), C09C, C09D (angiotensin II antagonists, plain, angiotensin II 
antagonists, combinations) divided by the number of treated patients as estimated by the 
model. For Germany, England and Spain, costs were derived from a bottom-up 
perspective according to estimates available in the published literature. The resulting 
parameter values and their sources for each country are summarised in Table 3.  
Medical costs of cardiovascular events were assessed as a weighted average depending on 
country-specific number of events attributable to hypertension and associated 
hospitalization rates (Appendix B).  
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Table 3 - Cost parameters (mean per subjects) 
 ITALY ENGLAND FRANCE GERMANY SPAIN 
Drug cost € 280[33] € 37[34] € 244[35] € 213[36] € 974[37] 
Hospitalization cost € 3,939[38] € 3,511[39] € 3,543[40, 41] € 3,786[42, 43] € 4,350[44] 
 
Scenarios and sensitivity analyses 
The impact of improving adherence was compared against the current values for each 
country as reported in Table 2. In the main scenario it was assumed that the number of 
subjects treated and having an adherence rate to antihypertensive treatment equal or 
above 80%, would increased to 70% in all Countries. The model was run at current 
adherence levels and at 70% of treated subjects, in order to estimate the difference in CV 
events and related costs under the two scenarios.  
Probabilistic sensitivity analysis was also carried out through Monte Carlo simulations 
based on a range of probabilities for each parameter considered in the model (Appendix 
C). Sensitivity analysis enabled the estimation of 95% confidence intervals (CI 95%) 
around the mean value, using the percentile method to identify the upper and lower 95% 
bounds over 5,000 simulations. The model and the sensitivity analysis were developed in 




Table 4 reports the predicted number and cost of all CV events related to hypertension for 
each country and aggregated across all 5 countries. Over the 10-year time horizon, a total 
of almost 8.6 million CV events are predicted based on current demographic, 
epidemiological and adherence data (32% were estimated to occur in Germany, 20% in 
France and Italy, and 15% and 12% in Spain and England respectively). The total cost of 
CV events attributable to hypertension was estimated to exceed € 51.1 billion over a time 
span of 10 years (range: € 4.1 in England and € 17.8 in Germany). 
 
Table 4 - Base case results: number and cost of CV events attributable to hypertension 
BASE-CASE ITALY GERMANY SPAIN FRANCE ENGLAND TOTAL 
Mean number of CV events  
Diagnosed Subjects 934,558 2,409,410 650,129 940,998 461,025 5,396,120 
Undiagnosed Subjects 424,749 934,768 552,331 867,587 425,886 3,205,321 
Total CV Events 1,359,307 3,344,178 1,202,460 1,808,585 886,911 8,601,441 
Mean cost per subjects  
Diagnosed Subjects € 1,305 € 1,170 € 2,709 € 1,158 € 704 € 7,046 
Undiagnosed Subjects € 914 € 969 € 948 € 822 € 815 € 4,468 
Mean total cost per subject € 2,219 € 2,139 € 3,657 € 1,980 € 1,518 € 11,513 
Total Cost  
Diagnosed Subjects (€ Billion) € 6.46 € 14.26 € 9.84 € 5.72 € 2.27 € 38.55 
Undiagnosed Subjects (€ Billion) € 1.67 € 3.54 € 2.40 € 3.07 € 1.87 € 12.56 
Total Hypertension Cost (€ Billion) € 8.14 € 17.80 € 12.25 € 8.79 € 4.14 € 51.11 
 
Considering only the costs associated with diagnosed and treated patients, drug cost is 
estimated, on average, to represent 37% (range: 10% in England and 71% in Spain) of the 
total cost of the disease and the remaining part being attributed to hospitalisations (Table 
5). In Italy, a total cost related to diagnosed and treated hypertensive patients of € 6.5 
billion (CI 95%: € 5.9 – 7.1 billion) was estimated over a 10 years horizon. Similarly, in 
France, the cost associated with hospitalization was estimated at € 3.3 billion (CI 95%: € 2.9 
– 3.7 billion) and the total expenditure for diagnosed subjects amounted to € 5.7 billion (CI 




Total costs related to diagnosed patients were much higher in Germany and Spain than in 
other countries. In Germany, where the prevalence of hypertension (Table 2) and of 
diagnosed subjects (Table 4) were both high, total expenditure was estimated to be € 14.3 
billion (CI 95%: € 12.9 – 15.5 billion). In Spain, the high cost associated with hypertensive 
patients was attributable to a total drug cost of € 7.0 billion (CI 95%: € 6.3 – 7.8 billion), 
higher than any other country and approximately three times the cost of hospitalizations 
(€ 2.8 billion CI 95%: € 2.5 – 3.2 billion). 
In England, drug costs of just € 0.2 billion (CI 95%: € 0.2 – 0.3 billion) were particularly 
low, corresponding to 10.6% of the total expenditure related to hypertensive treatment and 
hospitalization cost. These lower drug costs reflect a high proportion of generic drugs in 
the total drugs used, and low generic prices in the UK. 
 
Table 5  – Cost of drugs and hospitalisations of patients diagnosed with hypertension 
Country Diagnosed patient cost 
Hypertension Cost 
Mean cost IC 95% 
ITALY 
Drug Cost € 2,798,271,582 € 2,513,578,090 € 3,082,965,074 
Hospitalization cost € 3,698,571,798 € 3,299,348,488 € 4,097,795,108 
Total cost € 6,496,843,380 € 5,877,989,680 € 7,115,697,080 
GERMANY 
Drug Cost € 5,176,750,430 € 4,652,232,211 € 5,701,268,650 
Hospitalization cost € 9,176,695,193 € 8,155,337,277 € 10,198,053,110 
Total cost € 14,353,445,624 € 12,948,004,902 € 15,758,886,346 
SPAIN 
Drug Cost € 7,049,193,249 € 6,328,671,948 € 7,769,714,551 
Hospitalization cost € 2,843,658,554 € 2,525,597,354 € 3,161,719,755 
Total cost € 9,892,851,804 € 8,941,379,172 € 10,844,324,435 
FRANCE 
Drug Cost € 2,391,414,106 € 2,145,779,748 € 2,637,048,465 
Hospitalization cost € 3,341,557,203 € 2,970,025,694 € 3,713,088,712 
Total cost € 5,732,971,309 € 5,173,532,146 € 6,292,410,473 
ENGLAND 
Drug Cost € 241,130,763 € 216,762,528 € 265,498,998 
Hospitalization cost € 2,032,541,232 € 1,811,853,114 € 2,253,229,349 
Total cost € 2,273,671,995 € 1,945,276,478 € 2,602,067,511 
TOTAL 
Drug Cost € 10,607,566,882 € 9,528,352,576 € 11,686,781,187 
Hospitalization cost € 18,249,365,426 € 16,236,564,573 € 20,262,166,278 
Total cost € 28,856,932,308 € 25,944,803,205 € 31,769,061,410 
 
Finally, the study estimated that, by increasing to 70% the adherence to treatment in all 
countries, it would be possible to reduce direct healthcare costs for hypertension by about 
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€ 323 million (CI 95%:-€ 304, -€ 342) (Figure 2) equal to to 82,235 fewer CV events (24,058 in 
Italy, 7,870 in Germany, 18,870 in Spain, 24,855 in France and 6,553 in England). 
By looking at savings at national level, it can be seen that countries are clustered into two 
groups. In the first, cost reductions due to increased adherence are in the order of € 20/30 
million (Germany and England); in the second group there is a substantially higher impact 
of increased adherence, with cost reductions exceeding € 80 million (Italy, Spain and 
France). The reasons for the lower level of cost reduction in the first group differ between 
the two countries: Germany (average savings € 26.6 million CI 95%: -€ 56.5 - € 3.3) is 
characterized by adherence to treatment at the baseline (66.9%) which is already very close 
to the target value of 70%, whereas in England (average savings € 28.1 million CI 95%: -€ 
20.4 - € 35.7)  the cost of drugs is significantly lower than the European average, and 
therefore savings are mainly attributable to hospitalization cost. 
In the second group, the quite low adherence (range: 39.0% - 41.5%) and the non-negligible 
costs of drugs and hospitalization determine level of savings higher than € 80 million for 
each of the three counties: Italy (€ 97.3 million CI 95%: -€ 81.3 - -€ 113.3), Spain (€ 84.4 
million CI 95%: -€ 75.8 - -€ 92.0) and France (€ 87.4 million CI 95%: -€ 70.2 - -€ 104.5). 
 
Figure 3 – Estimation of costs avoided due to an increase in adherence (Scenario 1 – Scenario 2) – Average 




Discussion and conclusion 
This is the first study which aims to estimate costs associated with non-adherence to anti-
hypertensive treatment in five European countries. A recent study reported that, 
comparing current adherence rates of approximately 40% with hypothetical full adherence 
of 100%, non-adherence can be estimated to entail a clinical and financial burden of over 
8.5 million CV events and about $ 72 billion in the USA15over 10 years. Our analysis 
assumed a more realistic scenario, in which adherence levels in the five European 
Countries could be increased from current levels to 70% of treated patients: in other 
words, a scenario where 70% of patients prescribed for an antihypertensive treatment, take 
at least 80% of their given regimen. Our analysis indicates that this would reduce CV-
related health care costs by € 323 million (CI 95%: -€ 304 - -€ 342) over a 10 years period.  
A study by Leal et al. (2006)3 estimated the annual economic impact of CV through the 
main national sources of epidemiological and financial data. In line with our results over 
the course of 10 years, Leal et al. estimated an annual average expenditure of € 16.1 billion 
(2003) for the 5 Countries included in our analysis (drug, primary, outpatient, emergency, 
and inpatient care) or € 14.7 billion (2003) for outpatient and hospitalisation costs only. If 
one third of the total events estimated by Leal et al. are assumed to be associated with 
hypertension,17 the total cost per year would be €4.8 billion per year, close to the € 5.1 
billion (CI 95% € 4.7 – 5.5 billion) per year estimated in our study.  
The present study has some limitations, mostly attributable to assumptions and estimates 
which were necessary to overcome the lack of standardized data for the five countries of 
interest. Our epidemiological data were either obtained from statistics provided by 
national institutions or extrapolated estimates from scientific literature. Our estimates for 
adherence rates were taken from a number of different studies which could have used 
definitions different to that given in our study16. 
Likewise, costs were obtained from a number of data sources using methods and 
definitions which may have varied from one country to the other. This applies to both 
drug costs and hospital costs, which were not completely consistently derived across 
countries. However, use of probabilistic sensitivity analysis has allowed us to capture and 
explore the variability in the main parameters of the model. 
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The estimation of risk and of the number of CV events related to hypertension was based 
on a well-known cohort study – the Framingham Heart Study – that consists of a non-
European population,15,17 and no adjustments were made for ethnic composition in each 
country. However, calculations were adjusted for the age and sex structure of each 
population, and a 2008 study45 reported a high correlation between the cardiovascular 
risks estimated in the Framingham study and those observed in a population of European 
subjects (SCORE46, 47). Indeed, the Framingham risk equations predict the risk of 
developing a first CV event and no assumption were considered in our analysis because of 
no data available. 
In conclusion, our study represents the first attempt in Europe to estimate the costs 
associated with non-adherence to anti-hypertensive treatment, using a probabilistic 
prevalence based model in 5 European countries. Despite its limitations, this analysis 
should help decision makers to better understand the clinical and economic importance of 
improving adherence at national level, and will help inform strategies to improve 
adherence to therapy as one key issue of antihypertensive medical therapy. All actions 
taken to increase patient compliance to anti-hypertensive therapies, such as psychological 
support to enhance patient's motivation, patient’s reminders, and use of fixed dose 
combination therapies to decrease pill burden, should be assessed by policy makers and 
healthcare budget holders within a framework that considers not only the short term costs 
of these interventions, but also possible offsetting costs due to fewer hospitalizations, and 
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